---
title: The Effect of Propolis Administration on Cholesterol Level in Diabetic Type 2 Patients
nct_id: NCT06903546
overall_status: RECRUITING
phase: PHASE4
sponsor: Indonesia University
study_type: INTERVENTIONAL
primary_condition: Diabetes Mellitus Type 2
countries: Indonesia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06903546.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06903546"
ct_last_update_post_date: 2025-04-03
last_seen_at: "2026-05-12T06:14:35.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of Propolis Administration on Cholesterol Level in Diabetic Type 2 Patients

**Official Title:** The Effect of Propolis Administration on Low Density Lipoprotein and High Density Lipoprotein in Diabetic Type 2 Patients in Central Jakarta

**NCT ID:** [NCT06903546](https://clinicaltrials.gov/study/NCT06903546)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 64
- **Lead Sponsor:** Indonesia University
- **Conditions:** Diabetes Mellitus Type 2
- **Start Date:** 2025-03-18
- **Completion Date:** 2025-07-31
- **CT.gov Last Update:** 2025-04-03

## Brief Summary

The goal of this clinical trial is to learn if propolis administration works to change the level of Low Density Lipoprotein (LDL) and High Density Lipoprotein cholesterol (HDL) in diabetic type 2 patients.

The main questions it aims to answer are:

\- Is giving 1 drops/ 10kg/ times, twice daily for 8 weeks will change the level of LDL and HDL level in diabetic type 2 patients compared to placebo? Researchers will compare propolis to a placebo (a look-alike substance that contains no drug) to see if propolis works to change LDL and HDL cholesterol level.

Participants will:

* Take propolis or a placebo, 2 times daily with given dose (1 drops/10 kg/times) every day for 2 months
* Visit the sub-district health centre once every 2 weeks for checkups
* Get their blood checked before and after intervention

## Detailed Description

Subject allocation into groups will be made by third party to ensure masking/ blinding protocol.

Data that will be taken from participants :

* Private information
* Medication history (for type 2 Diabetes Mellitus)
* Food intake (calories, fats, carbohydrate, protein, and flavonoid intake)
* Physical activity status

## Eligibility

- **Minimum age:** 35 Years
- **Maximum age:** 59 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Controlled Diabetes Mellitus type 2 with HbA1c \<7.5%
* BMI 23-35 kg/m2
* On anti-cholesterol therapy

Exclusion Criteria:

* Using injection therapy (insulin or GLP-1 RA)
* History of bees product allergy
* Active smoker
* Consuming alcohol
* Altered liver (ALT\>35 IU/L) and kidney (eGFR\<90 mL/min) function
* Pregnant and breastfeeding women
* History of cardiovascular disease (heart attack, stroke)
```

## Arms

- **Intervention group** (EXPERIMENTAL) — This group will receive the intervention, which in this study is propolis with dose given 1 drop/kg/time given, 2 times daily, for 8 weeks (2 months)
- **Control group** (PLACEBO_COMPARATOR) — This group will receive placebo (a look-alike substance that contains no drug) with dose given 1 drop/kg/time given, 2 times daily, for 8 weeks (2 months)

## Interventions

- **Propolis drops** (DRUG) — The intervention given is propolis drops that are approved by Indonesian Food and Drug Authority
- **Placebo** (OTHER) — The given placebo are look-alike substance with no effect

## Primary Outcomes

- **Low Density Lipoprotein** _(time frame: 8 weeks)_ — LDL level will be measured twice, before and after intervention
- **High Density Lipoprotein** _(time frame: 8 weeks)_ — HDL will be measured twice, before and after intervention

## Locations (1)

- University of Indonesia Faculty of Biomedical Science, Jakarta, Indonesia — _RECRUITING_

## Recent Field Changes (last 30 days)

- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `locations.university of indonesia faculty of biomedical science|jakarta||indonesia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06903546.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06903546*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*